Top

Published in:

01-06-2017 | Laboratory Investigation

MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation

Authors: Chen Jin, Minhong Li, Yian Ouyang, Zhigang Tan, Yugang Jiang

Published in: Journal of Neuro-Oncology | Issue 2/2017

Abstract

Glioma is one of the most lethal malignancies, and increasing reports revealed that microRNAs (miRNAs), a class of small non-coding RNAs, play a critical role in the development and pathology of human gliomas. MiR-424 has been found to be dysregulated in many different types of human cancers. However, the clinical significance and function of miR-424 in glioma remains unclear. Here, based on RTq-PCR analysis in 148 clinical specimens, we found miR-424 expression was significantly decreased in glioma tumor tissues than in adjacent non-neoplastic brain tissues, and decreased miR-424 expression was associated with glioma KPS (P = 0.009) and high grades (P = 0.029). In vitro cellular function assays further revealed that miR-424 inhibited cell invasion and migration, and promoted cell apoptosis. In addition, based on DNA methylation analysis on clinical specimens and cell lines, we found miR-424 promoter CpG island was frequently methylated and correlated with glioma high grades (P = 0.035) and IDH mutation status (P = 0.042). Moreover, the promoter CpG island was demethylated by 5-aza-2′-deoxycytidine treatment in a time-dependent manner and the expression levels of miR-424 were gradually induced and increased. Taken together, our data suggest that the promoter region CpG island methylation is associated with tumor suppressive miR-424 silencing and the pathology of human gliomas.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114(2):97–109. doi:10.1007/s00401-007-0243-4 CrossRefPubMedPubMedCentral

Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin 64(1):9–29. doi:10.3322/caac.21208 CrossRefPubMed

Westphal M, Lamszus K (2011) The neurobiology of gliomas: from cell biology to the development of therapeutic approaches. Nat Rev Neurosci 12(9):495–508. doi:10.1038/nrn3060 CrossRefPubMed

Grossman SA, Ye X, Piantadosi S, Desideri S, Nabors LB, Rosenfeld M, Fisher J, Consortium NC (2010) Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States. Clin Cancer Res 16(8):2443–2449. doi:10.1158/1078-0432.CCR-09-3106 CrossRefPubMedPubMedCentral

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO, European Organisation for R, Treatment of Cancer Brain T, Radiotherapy G, National Cancer Institute of Canada Clinical Trials G (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996. doi:10.1056/NEJMoa043330 CrossRefPubMed

Ambros V (2004) The functions of animal microRNAs. Nature 431(7006):350–355. doi:10.1038/nature02871 CrossRefPubMed

Iorio MV, Croce CM (2009) MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 27(34):5848–5856. doi:10.1200/JCO.2009.24.0317 CrossRefPubMedPubMedCentral

Kim VN (2005) Small RNAs: classification, biogenesis, and function. Mol Cells 19(1):1–15CrossRefPubMed

Parsons DW, Jones S, Zhang X, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Siu IM, Gallia GL, Olivi A, McLendon R, Rasheed BA, Keir S, Nikolskaya T, Nikolsky Y, Busam DA, Tekleab H, Diaz LA Jr, Hartigan J, Smith DR, Strausberg RL, Marie SK, Shinjo SM, Yan H, Riggins GJ, Bigner DD, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, Kinzler KW (2008) An integrated genomic analysis of human glioblastoma multiforme. Science 321(5897):1807–1812. doi:10.1126/science.1164382 CrossRefPubMedPubMedCentral

10.

Wang Y, Wang M, Wei W, Han D, Chen X, Hu Q, Yu T, Liu N, You Y, Zhang J (2016) Disruption of the EZH2/miRNA/beta-catenin signaling suppresses aerobic glycolysis in glioma. Oncotarget. doi:10.18632/oncotarget.10370

11.

Xue J, Zhou A, Wu Y, Morris SA, Lin K, Amin S, Verhaak R, Fuller G, Xie K, Heimberger AB, Huang S (2016) miR-182-5p Induced by STAT3 activation promotes glioma tumorigenesis. Cancer Res 76(14):4293–4304. doi:10.1158/0008-5472.CAN-15-3073 CrossRefPubMedPubMedCentral

12.

Yin D, Ogawa S, Kawamata N, Leiter A, Ham M, Li D, Doan NB, Said JW, Black KL, Phillip Koeffler H (2013) miR-34a functions as a tumor suppressor modulating EGFR in glioblastoma multiforme. Oncogene 32(9):1155–1163. doi:10.1038/onc.2012.132 CrossRefPubMed

13.

Oneyama C, Kito Y, Asai R, Ikeda J, Yoshida T, Okuzaki D, Kokuda R, Kakumoto K, Takayama K, Inoue S, Morii E, Okada M (2013) MiR-424/503-mediated Rictor upregulation promotes tumor progression. PloS ONE 8(11):e80300. doi:10.1371/journal.pone.0080300 CrossRefPubMedPubMedCentral

14.

Long XH, Mao JH, Peng AF, Zhou Y, Huang SH, Liu ZL (2013) Tumor suppressive microRNA-424 inhibits osteosarcoma cell migration and invasion via targeting fatty acid synthase. Exp Ther Med 5(4):1048–1052. doi:10.3892/etm.2013.959 PubMedPubMedCentral

15.

Yu L, Ding GF, He C, Sun L, Jiang Y, Zhu L (2014) MicroRNA-424 is down-regulated in hepatocellular carcinoma and suppresses cell migration and invasion through c-Myb. PloS ONE 9(3):e91661. doi:10.1371/journal.pone.0091661 CrossRefPubMedPubMedCentral

16.

Yang H, Zheng W, Shuai X, Chang RM, Yu L, Fang F, Yang LY (2015) MicroRNA-424 inhibits Akt3/E2F3 axis and tumor growth in hepatocellular carcinoma. Oncotarget 6(29):27736–27750. doi:10.18632/oncotarget.4811 CrossRefPubMedPubMedCentral

17.

Faraoni I, Laterza S, Ardiri D, Ciardi C, Fazi F, Lo-Coco F (2012) MiR-424 and miR-155 deregulated expression in cytogenetically normal acute myeloid leukaemia: correlation with NPM1 and FLT3 mutation status. J Hematol Oncol 5:26. doi:10.1186/1756-8722-5-26 CrossRefPubMedPubMedCentral

18.

Xu J, Li Y, Wang F, Wang X, Cheng B, Ye F, Xie X, Zhou C, Lu W (2013) Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene 32(8):976–987. doi:10.1038/onc.2012.121 CrossRefPubMed

19.

Li Q, Qiu XM, Li QH, Wang XY, Li L, Xu M, Dong M, Xiao YB (2015) MicroRNA-424 may function as a tumor suppressor in endometrial carcinoma cells by targeting E2F7. Oncol Rep 33(5):2354–2360. doi:10.3892/or.2015.3812 PubMed

20.

Zhang H, Wang X, Chen Z, Wang W (2015) MicroRNA-424 suppresses estradiol-induced cell proliferation via targeting GPER in endometrial cancer cells. Cell Mol Biol 61(7):96–101PubMed

21.

Wu CT, Lin WY, Chang YH, Lin PY, Chen WC, Chen MF (2015) DNMT1-dependent suppression of microRNA424 regulates tumor progression in human bladder cancer. Oncotarget 6(27):24119–24131. doi:10.18632/oncotarget.4431 CrossRefPubMedPubMedCentral

22.

Banyard J, Chung I, Wilson AM, Vetter G, Le Bechec A, Bielenberg DR, Zetter BR (2013) Regulation of epithelial plasticity by miR-424 and miR-200 in a new prostate cancer metastasis model. Sci Rep 3:3151. doi:10.1038/srep03151 CrossRefPubMedPubMedCentral

23.

Li Z, Zhang G, Li D, Jie Z, Chen H, Xiong J, Liu Y, Cao Y, Jiang M, Le Z, Tan S (2015) Methylation-associated silencing of miR-495 inhibit the migration and invasion of human gastric cancer cells by directly targeting PRL-3. Biochem Biophys Res Commun 456(1):344–350. doi:10.1016/j.bbrc.2014.11.083 CrossRefPubMed

24.

Shen R, Pan S, Qi S, Lin X, Cheng S (2010) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 in gastric cancer. Biochem Biophys Res Commun 394(4):1047–1052. doi:10.1016/j.bbrc.2010.03.121 CrossRefPubMed

25.

Yu H, Yang W (2016) MiR-211 is epigenetically regulated by DNMT1 mediated methylation and inhibits EMT of melanoma cells by targeting RAB22A. Biochem Biophys Res Commun 476(4):400–405. doi:10.1016/j.bbrc.2016.05.133 CrossRefPubMed

26.

Ghasemi A, Fallah S, Ansari M (2016) MiR-153 as a tumor suppressor in glioblastoma multiforme is downregulated by DNA methylation. Clin Lab 62(4):573–580PubMed

27.

Cui H, Mu Y, Yu L, Xi YG, Matthiesen R, Su X, Sun W (2016) Methylation of the miR-126 gene associated with glioma progression. Fam Cancer 15(2):317–324. doi:10.1007/s10689-015-9846-4 CrossRefPubMed

28.

Tivnan A, Zhao J, Johns TG, Day BW, Stringer BW, Boyd AW, Tiwari S, Giles KM, Teo C, McDonald KL (2014) The tumor suppressor microRNA, miR-124a, is regulated by epigenetic silencing and by the transcriptional factor, REST in glioblastoma. Tumour Biol 35(2):1459–1465. doi:10.1007/s13277-013-1200-6 CrossRefPubMed

29.

Ning X, Shi Z, Liu X, Zhang A, Han L, Jiang K, Kang C, Zhang Q (2015) DNMT1 and EZH2 mediated methylation silences the microRNA-200b/a/429 gene and promotes tumor progression. Cancer Lett 359(2):198–205. doi:10.1016/j.canlet.2015.01.005 CrossRefPubMed

30.

Chen B, Duan L, Yin G, Tan J, Jiang X (2013) Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells—Cdc2 activity is up-regulated by targeting WEE1. Clinics 68(6):825–833. doi:10.6061/clinics/2013(06)17 CrossRefPubMedPubMedCentral

31.

Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL (2015) TWIST1-induced miR-424 reversibly drives mesenchymal programming while inhibiting tumor initiation. Cancer Res 75(9):1908–1921. doi:10.1158/0008-5472.CAN-14-2394 CrossRefPubMedPubMedCentral

32.

Nakashima T, Jinnin M, Etoh T, Fukushima S, Masuguchi S, Maruo K, Inoue Y, Ishihara T, Ihn H (2010) Down-regulation of mir-424 contributes to the abnormal angiogenesis via MEK1 and cyclin E1 in senile hemangioma: its implications to therapy. PloS ONE 5(12):e14334. doi:10.1371/journal.pone.0014334 CrossRefPubMedPubMedCentral

33.

Ruiz-Llorente L, Ardila-Gonzalez S, Fanjul LF, Martinez-Iglesias O, Aranda A (2014) microRNAs 424 and 503 are mediators of the anti-proliferative and anti-invasive action of the thyroid hormone receptor beta. Oncotarget 5(10):2918–2933. doi:10.18632/oncotarget.1577 CrossRefPubMedPubMedCentral

34.

Chen Z, Wang L, Wang Q, Li W (2010) Histone modifications and chromatin organization in prostate cancer. Epigenomics 2(4):551–560. doi:10.2217/epi.10.31 CrossRefPubMedPubMedCentral

35.

Murr R (2010) Interplay between different epigenetic modifications and mechanisms. Adv Genet 70:101–141. doi:10.1016/B978-0-12-380866-0.60005-8 PubMed

36.

Shaknovich R (2013) Gene expression and epigenetic deregulation. Adv Exp Med Biol 792:133–150. doi:10.1007/978-1-4614-8051-8_6 CrossRefPubMed

37.

Jones C, Baker SJ (2014) Unique genetic and epigenetic mechanisms driving paediatric diffuse high-grade glioma. Nat Rev Cancer. doi:10.1038/nrc3811

38.

Sharma S, Kelly TK, Jones PA (2010) Epigenetics in cancer. Carcinogenesis 31(1):27–36. doi:10.1093/carcin/bgp220 CrossRefPubMed

39.

Watanabe K, Amano Y, Ishikawa R, Sunohara M, Kage H, Ichinose J, Sano A, Nakajima J, Fukayama M, Yatomi Y, Nagase T, Ohishi N, Takai D (2015) Histone methylation-mediated silencing of miR-139 enhances invasion of non-small-cell lung cancer. Cancer Med 4(10):1573–1582. doi:10.1002/cam4.505 CrossRefPubMedPubMedCentral

Title: MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation
Authors: Chen Jin
Minhong Li
Yian Ouyang
Zhigang Tan
Yugang Jiang
Publication date: 01-06-2017
Publisher: Springer US
Published in: Journal of Neuro-Oncology / Issue 2/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-017-2438-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

MiR-424 functions as a tumor suppressor in glioma cells and is down-regulated by DNA methylation

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Patterns of care and outcomes of multi-agent versus single-agent chemotherapy as part of multimodal management of low grade glioma

Pathological analysis of the surgical margins of resected glioblastomas excised using photodynamic visualization with both 5-aminolevulinic acid and fluorescein sodium

Fatigue in patients with low grade glioma: systematic evaluation of assessment and prevalence

Atypical and anaplastic meningioma: outcomes in a population based study

The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies

Clinical features and long-term outcomes of pediatric spinal meningiomas